ArticleThe oncologist2025

Feasibility and tolerability of anlotinib plus PD-1 blockades as rechallenge immunotherapy in previously treated advanced ESCC: a retrospective study.

Yonggui Hong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.